Literature DB >> 33170937

Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Fionnuala Ní Áinle1,2,3,4, Barry Kevane1,3,4.   

Abstract

Recurrent venous thromboembolism (VTE, or deep vein thrombosis and pulmonary embolism) is associated with mortality and long-term morbidity. The circumstances in which an index VTE event occurred are crucial when personalized VTE recurrence risk is assessed. Patients who experience a VTE event in the setting of a transient major risk factor (such as surgery associated with general anesthesia for >30 minutes) are predicted to have a low VTE recurrence risk following discontinuation of anticoagulation, and limited-duration anticoagulation is generally recommended. In contrast, those patients whose VTE event occurred in the absence of risk factors or who have persistent risk factors have a higher VTE recurrence risk. Here, we review the literature surrounding VTE recurrence risk in a range of clinical conditions. We describe gender-specific risks, including VTE recurrence risk following hormone- and pregnancy-associated VTE events. Finally, we discuss how the competing impacts of VTE recurrence and bleeding have shaped international guideline recommendations.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33170937      PMCID: PMC7656931          DOI: 10.1182/bloodadvances.2020002268

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  59 in total

1.  Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Authors:  Francis Couturaud; Olivier Sanchez; Gilles Pernod; Patrick Mismetti; Patrick Jego; Elisabeth Duhamel; Karine Provost; Claire Bal dit Sollier; Emilie Presles; Philippe Castellant; Florence Parent; Pierre-Yves Salaun; Luc Bressollette; Michel Nonent; Philippe Lorillon; Philippe Girard; Karine Lacut; Marie Guégan; Jean-Luc Bosson; Silvy Laporte; Christophe Leroyer; Hervé Décousus; Guy Meyer; Dominique Mottier
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

2.  D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Authors:  Clive Kearon; Frederick A Spencer; Denis O'Keeffe; Sameer Parpia; Sam Schulman; Trevor Baglin; Scott M Stevens; Scott Kaatz; Kenneth A Bauer; James D Douketis; Steven R Lentz; Craig M Kessler; Stephan Moll; Jean M Connors; Jeffrey S Ginsberg; Luciana Spadafora; Jim A Julian
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

3.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Authors:  J A Heit; D N Mohr; M D Silverstein; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

4.  Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.

Authors:  Martha L Louzada; Marc Carrier; Alejandro Lazo-Langner; Vi Dao; Michael J Kovacs; Timothy O Ramsay; Marc A Rodger; Jerry Zhang; Agnes Y Y Lee; Guy Meyer; Philip S Wells
Journal:  Circulation       Date:  2012-06-07       Impact factor: 29.690

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

6.  Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.

Authors:  Cynthia Wu; Ghazi S Alotaibi; Khalid Alsaleh; Lori-Ann Linkins; M Sean McMurtry
Journal:  Thromb Res       Date:  2014-12-02       Impact factor: 3.944

7.  Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study.

Authors:  Benilde Cosmi; Cristina Legnani; Alberto Tosetto; Vittorio Pengo; Angelo Ghirarduzzi; Sophie Testa; Domenico Prisco; Daniela Poli; Armando Tripodi; Francesco Marongiu; Gualtiero Palareti
Journal:  Blood       Date:  2009-11-16       Impact factor: 22.113

8.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

9.  Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Authors:  Martin H Prins; Anthonie W A Lensing; Paolo Prandoni; Philip S Wells; Peter Verhamme; Jan Beyer-Westendorf; Rupert Bauersachs; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Ajay K Kakkar; Bonno van Bellen; Akos F Pap; Martin Homering; Miriam Tamm; Jeffrey I Weitz
Journal:  Blood Adv       Date:  2018-04-10

10.  VTE risk assessment in pregnancy.

Authors:  Karl Ewins; Fionnuala Ní Ainle
Journal:  Res Pract Thromb Haemost       Date:  2019-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.